Diagnostic contrast media
for magnetic resonance imaging (MRI) are o
ften applied to enhance the signal o
fblood allowing
for quantitative de
finition o
f vascular
functional characteristics including tissue blood volume,
flow, and leakiness. Well-tolerated and sa
fe macromolecular
formulations are currently being sought that remainin the blood
for a relatively long period and that leak selectively
from diseased vessels, particularly cancer vessels.We synthesized a new class o
f macromolecular, water-soluble MRI contrast media by introducing two divergingpolylysine cascade ampli
fiers at each end o
f a poly(ethylene glycol) (PEG) backbone,
followed by substitution o
fterminal lysine amino groups with Gd-DTPA chelates. Four candidate PEG cascade conjugates are reportedhere, PEG3400-Gen4-(Gd-DTPA)
8, PEG6000-Gen4-(Gd-DTPA)
8, PEG12000-Gen4-(Gd-DTPA)
8, and PEG3400-Gen5-(Gd-DTPA)
13 with descriptions o
f their basic physical, biological, and kinetic properties, including realand e
ffective molecular sizes, proton T1 relaxivities in water and plasma, partition coe
fficients, osmolalities,chelate stability, stability in plasma, stability to autoclaving, certain in vivo pharmacokinetics (blood hal
f-li
fe,blood clearance, volume o
f distribution), and whole body elimination pro
files in normal rodents. These candidatePEG-core cascade MRI contrast media showed a range o
f e
ffective molecular sizes similar to proteins weighing74-132 kDa, although their actual molecular weights were much smaller, 12-20 kDa. All compounds exhibiteda narrow range o
f size dispersity and relatively high T1 relaxivities (approximately 3 times the value
forunconjugated Gd-DTPA at 2 T and 37
f">C). Representative compounds also showed a high degree o
f hydrophilicity,stability in solution bu
ffer and plasma, and lack o
f binding to proteins. The two candidate compounds with thelargest e
ffective molecular sizes, PEG12000-Gen4-(Gd-DTPA)
8 and PEG3400-Gen5-(Gd-DTPA)
13, had longerblood hal
f-lives, 36 and 73 min, respectively (monoexponential kinetics
for both), and showed strong, prolongedMRI enhancement o
f vessels. Results also indicate that in vivo pharmacokinetics and bodily elimination pro
filescan be adjusted by the selection o
f molecular size
for the PEG core and the selection o
f the ampli
fication degreeo
f the cascade polylysine clusters. The initially evaluated compounds
from this new class o
f contrast media showacceptable, desirable characteristics in many, but not all, respects. Further e
fforts are directed toward candidatemacromolecules having higher thermodynamic stability, higher degree o
f substitution by gadolinium chelates,and more rapid bodily elimination.